Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome
Status:
Completed
Trial end date:
2020-10-27
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to gain a preliminary understanding of the safety of
sirolimus in Sturge-Weber syndrome (SWS) and determine best outcomes to be used to assess the
utility of sirolimus for the treatment of cognitive impairments related to Sturge-Weber
syndrome.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Anne Comi, MD
Collaborators:
Children's Hospital Medical Center, Cincinnati Faneca 66 Foundation National Institute of Neurological Disorders and Stroke (NINDS) National Institutes of Health (NIH) Pfizer